IONS

Business Context and Reporting Period

Company: Isis Pharmaceuticals, Inc. (now Ionis Pharmaceuticals)

Filing Type: Form 10-K (Annual Report)

Period Ended: December 31, 2005

Isis is a biopharmaceutical company focused on RNA-based drug discovery, specifically antisense technology, and the TIGER biosensor system for infectious disease identification. The company operates two primary segments: Drug Discovery and Development (antisense therapeutics) and the Ibis Division (TIGER biosensor). As of the reporting date, the company had one approved product, Vitravene, and a pipeline of 13 antisense drugs in various stages of development, alongside the commercialization of TIGER systems for government agencies.

Key Financial Metrics

Note: The company reported a net loss for the period. Margins are not applicable due to the net loss position.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by 6% to $40.1 million, primarily due to a reduction in revenue from the Eli Lilly collaboration ($10.8 million in 2005 vs. $15.7 million in 2004) following the completion of certain milestones and the extension of the agreement to focus on fewer targets.
• Expense Reduction: Operating expenses decreased significantly by 39% to $97.3 million. This was driven by a major restructuring in early 2005, which reduced R&D and G&A costs by $37.2 million through workforce reductions, facility consolidations, and the discontinuation of lower-priority drug programs (e.g., Affinitak, ISIS 14803, ISIS 104838).
• Debt Conversion: In August 2005, the company converted a $100 million interest-free loan from Eli Lilly into 2.5 million shares of common stock. This action substantially reduced long-term debt obligations and improved stockholders' equity, turning a deficit of $72.1 million in 2004 into positive equity of $2.7 million in 2005.
• Restructuring Charges: The company recorded $7.0 million in restructuring costs in 2005, compared to $32.4 million in 2004. The 2005 charge included employee terminations and facility closures, partially offset by a $1.5 million gain on the sale of three buildings.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Liquidity: Management believes current resources are sufficient to meet anticipated requirements through 2007.
• Drug Development: Positive Phase 1 results were reported for ISIS 301012 (cholesterol) and ISIS 113715 (diabetes), leading to the initiation of Phase 2 programs. The company aims to report Phase 2 data for these candidates in 2006.
• Ibis Division: The company plans to continue delivering TIGER biosensor systems to government partners and begin shipping infectious organism ID kits in 2006.

Risks and Contingencies

• Profitability: The company has incurred losses since inception and expects to incur additional operating losses in the near future. It has accumulated losses of approximately $770.8 million as of December 31, 2005.
• Government Contract Reliance: The Ibis division relies heavily on U.S. government contracts (30% of total revenue in 2005). These contracts can be terminated at the government's convenience, posing a risk to future revenue.
• Collaboration Dependency: Revenue is heavily dependent on partnerships (e.g., Lilly, Pfizer, Alnylam). Failure of partners to fund programs or achieve milestones could negatively impact the company.
• Legal Proceedings: An arbitration demand was filed by Ajinomoto Co., Inc. regarding a 1994 license agreement. The company estimates a potential loss range of $0 to $2.1 million but believes the claim is without merit.
• Regulatory Approval: All product candidates require extensive clinical testing and regulatory approval, which is uncertain and costly.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $94.4 million cash balance to fund operations through 2007 without additional financing, given the continued net burn rate.
• Debt Covenants: Review the terms of the Silicon Valley Bank term loan ($20.2 million outstanding) and the 5.5% Convertible Subordinated Notes ($125.0 million outstanding) for liquidity covenants and maturity dates.
• Revenue Concentration: Assess the risk associated with the top partners, which accounted for significant portions of revenue (e.g., Lilly at 27% in 2005).
• Restructuring Impact: Confirm that the cost savings from the 2005 restructuring are sustainable and not offset by new development costs for the expanded Phase 2 programs.
• Intellectual Property: Verify the status of the approximately 1,500 issued patents and the outcome of the Ajinomoto arbitration.